Analysts See $-0.29 EPS for MannKind Corporation (MNKD)

February 20, 2018 - By Michael Pereira

 Analysts See $ 0.29 EPS for MannKind Corporation (MNKD)

Analysts expect MannKind Corporation (NASDAQ:MNKD) to report $-0.29 EPS on March, 15.They anticipate $0.10 EPS change or 52.63 % from last quarter’s $-0.19 EPS. After having $-0.31 EPS previously, MannKind Corporation’s analysts see -6.45 % EPS growth. The stock increased 2.05% or $0.06 during the last trading session, reaching $2.99. About 3.34 million shares traded. MannKind Corporation (NASDAQ:MNKD) has declined 75.27% since February 20, 2017 and is downtrending. It has underperformed by 91.97% the S&P500.

MannKind Corporation (NASDAQ:MNKD) Ratings Coverage

Among 7 analysts covering Mannkind (NASDAQ:MNKD), 2 have Buy rating, 3 Sell and 2 Hold. Therefore 29% are positive. Mannkind had 15 analyst reports since August 3, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Griffin Securities on Monday, November 16. The firm has “Underweight” rating given on Wednesday, January 6 by Piper Jaffray. Piper Jaffray downgraded the stock to “Underweight” rating in Wednesday, September 9 report. Vetr downgraded the stock to “Strong-Buy” rating in Friday, August 28 report. RBC Capital Markets maintained it with “Outperform” rating and $9 target in Monday, August 3 report. The rating was downgraded by Maxim Group to “Hold” on Wednesday, November 1. The stock of MannKind Corporation (NASDAQ:MNKD) has “Buy” rating given on Friday, August 11 by Maxim Group. The stock has “Underperform” rating by RBC Capital Markets on Wednesday, November 4. H.C. Wainwright maintained it with “Buy” rating and $7.0 target in Tuesday, October 24 report. RBC Capital Markets maintained MannKind Corporation (NASDAQ:MNKD) on Tuesday, May 10 with “Underperform” rating.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. The company has market cap of $355.42 million. The Company’s approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. It currently has negative earnings.

More notable recent MannKind Corporation (NASDAQ:MNKD) news were published by: which released: “The Most Likely Reason Why MannKind Corporation Skyrocketed Higher Today” on January 25, 2018, also with their article: “MannKind – Afrezza Scripts Remain Modest” published on February 04, 2018, published: “MannKind – Afrezza Scripts Remain Underwhelming As Quarter Reaches Halfway Point” on February 17, 2018. More interesting news about MannKind Corporation (NASDAQ:MNKD) were released by: and their article: “MannKind Stock Rises As Afrezza Sales Remain Modest” published on January 27, 2018 as well as‘s news article titled: “Why MannKind Corporation Stock Is Falling Back to Earth Today” with publication date: January 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.